modelG04BX01

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:	MagnesiumHydroxide
ATC code:	G04BX01
route:	oral
compartments:	1
dosage:	1200	mg
volume of distribution:	0.3	L
clearance:	6	L/h
other parameters in model implementation

Magnesium hydroxide is an inorganic compound used as an antacid to relieve indigestion, heartburn, or dyspepsia, and as a laxative for short-term treatment of constipation. It is available over the counter and is commonly known as 'milk of magnesia.' Magnesium hydroxide is widely used and considered safe for short-term use. The drug is approved and widely used today.

Pharmacokinetics

No specific pharmacokinetic models or parameters for magnesium hydroxide in humans are described in published literature. Magnesium from magnesium hydroxide is absorbed to a very limited extent (<15%) in the gastrointestinal tract, with the majority being excreted unchanged in feces.

References

Scott, G, et al., & Rordorf, C (2004). Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. Clinical pharmacokinetics 43(5) 341–348. DOI:10.2165/00003088-200443050-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15080766
Smith, GW, & Correa, MT (2004). The effects of oral magnesium hydroxide administration on rumen fluid in cattle. Journal of veterinary internal medicine 18(1) 109–112. DOI:10.1892/0891-6640(2004)18<109:teoomh>2.0.co;2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14765740
Zhang, YF, et al., & Zhong, DF (2014). Effects of an Al(3+)- and Mg(2+)-containing antacid, ferrous sulfate, and calcium carbonate on the absorption of nemonoxacin (TG-873870) in healthy Chinese volunteers. Acta pharmacologica Sinica 35(12) 1586–1592. DOI:10.1038/aps.2014.95 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25327812

Parameters

Type	Name	Default	Description
Modelica.Units.SI.Mass	weight (from PK_1C)	75	patient weight (kg)
Modelica.Units.SI.SpecificVolume	VdPerKg (from PK_1C)	0.9	Volume of distribution (L/kg)
Modelica.Units.SI.MassFraction	F (from PK_1C)	0.8	bioavailiability (0-1)
Pharmacolibrary.Types.Clearance	Cl (from PK_1C)	20	clearance
Modelica.Units.SI.Time	adminTime (from PK_1C)	60	first administration time (s)
Modelica.Units.SI.Time	adminDuration (from PK_1C)	600	administration duration (s)
Modelica.Units.SI.Time	adminPeriod (from PK_1C)	86060	period of administration (default 8 hours)(s)
Pharmacolibrary.Types.Mass	adminMass (from PK_1C)	1000	administration mass (mg)
Integer	adminCount (from PK_1C)	8	number of dose administered (1)
Pharmacolibrary.Types.Volume	Vd (from PK_1C)	VdPerKg*weight	Volume of distribution (m3)
Pharmacolibrary.Types.MassConcentration	Cmin (from PK_1C)	0.004	minimal therapeutic range
Pharmacolibrary.Types.MassConcentration	Cmax (from PK_1C)	0.008	minimal therapeutic range
Pharmacolibrary.Types.MassConcentration	Ctox_peak (from PK_1C)	0.012	toxicity peak level
Pharmacolibrary.Types.MassConcentration	Ctox_trough (from PK_1C)	0.006	toxicity trough level
Pharmacolibrary.Types.TransferRate	ka (from PK_1C_enteral)	0.016666666666666666	first order absorption rate
Modelica.Units.SI.Time	Tlag (from PK_1C_enteral)	600	delay between oral administration and absorption (default 10min)

Connectors

Type	Name	Default	Description
Types.ConcentrationOutput	C_central (from PK_1C)
Interfaces.ConcentrationPort_b	centralCPort (from PK_1C)

Components

Type	Name	Description
Pharmacokinetic.NoPerfusedTissueCompartment	central (from PK_1C)
Pharmacokinetic.ClearanceDrivenElimination	elim (from PK_1C)
Sources.PeriodicDose	periodicDose (from PK_1C)
Modelica.Units.SI.Time	t1_2 (from PK_1C)	elimination half-life

Revisions

06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)